Sanofi used the American Diabetes Association Scientific Sessions as a platform to update investors on development plans for its late-stage diabetes pipeline, including a next-generation version of its market-leading basal insulin Lantus (insulin glargine) and a combination of Lantus with the glucagon-like peptide 1 agonist Lyxumia (lixisenatide). Both products are expected to be important growth drivers for Sanofi as Lantus approaches patent expiration in 2015.
Sanofi Sheds Light On Plans For LixiLan, U300 At ADA
Sanofi released positive data from two Phase III trials showing the next-generation insulin glargine U300 worked as well as Lantus in controlling blood sugar in patients with type 2 diabetes but with night-time benefits. The company also announced plans to initiate a Phase III trial studying a combination of the GLP-1 agonist Lyxumia with Lantus in the first half of 2014.